Selinexor in Combination With Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Selinexor (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

12 Dec 2023 Interim Results (n= As of July 26, 2023, n=44) assessing safety and efficacy of of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Jun 2023 Results safety analysis (n=14; as of data cutoff: 11 Feb 2023) presented at the 28th Congress of the European Haematology Association
15 Jun 2023 Results of interim analysis (As of Feb 24th 2023, n=28) assessing the preliminary efficacy, safety, and tolerability of the combination of Xd plus chemotherapy drugs in pts with RRMM presented at the 28th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com